60 results about "Epidermoid carcinoma" patented technology

The invention relates to a new application of furanodiene in pharmacy field, in particular to the application of the furanodiene in the preparation of medicines for treating the various malignant tumor diseases such as oophoroma, cervical carcinoma, gastric cancer, liver cancer, leucocythemia, lung cancer, oral carcinoma (epidermoid carcinoma), rectal adenocarcinoma, mammary cancer, malignant melanoma, colonic adenocarcinoma, nasopharyngeal carcinoma, carcinoma of prostate, etc. The invention also relates to the application of the furanodiene in the preparation of drugs for treating the diseases caused by herpesvirus, influenza virus and hepatitis B virus.

The invention provides 2-arylamine pyrimidine derivatives containing hydroxamic acid fragments shown in the formulas I and II. 2-arylamine pyrimidine containing carboxyl fragments is mainly used as a parent nucleus and is subjected to single-step condensation and related modification with hydroxylamine protected by THP to obtain a target compound. An experiment proves that the derivatives has the remarkable anti-proliferative effect on tumor cells (an overexpression EGFR human epidermal carcinoma cell line A431 and a human pulmonary carcinoma cell line H1975 resisting Gefitinib) related to EGFR tyrosine kinase activity on the cellular level, and tumor cells (a human cervical carcinoma cell line Hela, a human hepatoma cell line HepG2, a human promyelocytic acute leukemia cell line HL60, a human oral epidermoid carcinoma cell line KB, a human colon cancer cell line SW620) related to the HDAC histone acetylase activity, and the corresponding medicine for resisting cancer cells can be prepared. The general structural formula is shown in the description.

Provided are topical formulations comprising an Amyris alcohol and/or ester derivatives of Amyris alcohol which may be used for the treatment of diseases including herpes virus infection (e.g., HSV-1, HSV-2), epidermoid carcinoma, cold sores, and human papillomavirus. Amyris alcohols contemplated for use with the present invention include valerianol, beta-eudesmol, epi-gamma-eudesmol, elemol, alpha-eudesmol, and ester derivatives thereof.

The invention relates to secalonic acid I derived from penicillium oxalicum and application of the secalonic acid I for preparing a medicine for preventing human oral epidermoid carcinoma. The compound has a function of inhibiting human oral epidermoid carcinoma cell proliferation. The structural formula of the secalonic acid I is as shown in the specification. Through fermentation culture of Penicillium oxalicum IBPT-6, a fermented substance is prepared, and the compound is separated and purified from the fermented substance. Tests show that the compound has relatively high anti-tumor activity upon human oral epidermoid carcinoma cells KB. The compound can be used for preventing human oral epidermoid carcinoma cell proliferation inhibition medicines or anti-tumor medicines for studying human oral epidermoid carcinoma.

The invention discloses a 3-amino-3-hydroxymethyloxindole derivative shown as a formula (I) and a preparation method thereof. The 3-amino-3-hydroxymethyloxindole derivative is obtained by taking 3-diazooxindole, aniline and formaldehyde as raw materials, taking rhodium acetate as a catalyst and taking an organic solvent as a solvent through a one-step reaction. The preparation method disclosed by the invention can be used for constructing a compound with a plurality of functional groups in one step, and has the characteristics of high flexibility, high selectivity, efficient atom economy, high yield and simplicity and safety in operation and the like. The invention further discloses an inhibition effect of the 3-amino-3-hydroxymethyloxindole derivative shown as the formula (I) on proliferation of five types of tumor cells including human osteosarcoma cells (SJSA-1), human colorectal cancer cells (HCT-116), hepatocellular carcinoma cells (BEL7402), human oral epidermoid carcinoma cells (KB) and human T-cell leukemia cells (Jurkat).

The invention provides paclitaxel derivatives with a general structural formula (I) as described in the invention. The invention further provides application of the paclitaxel derivatives in preparation of drugs used for preventing or treating fibrosarcoma, liver cancer, lung cancer, leukemia, epidermoid carcinoma, breast cancer, prostatic cancer, lymphoma, stomach cancer, myeloma and pancreatic cancer. The derivatives synthesized in the invention have better water-solubility compared with paclitaxel and are superior to paclitaxel in the aspect of a plurality of anticancer effects.

The invention discloses application of nobiletin, and particularly discloses application of nobiletin in preparation of health products or medicines for preventing and/or treating oral cancer. Through the anti-proliferation effects of monomeric compounds, namely hesperetin, naringenin and nobiletin, in rutaceae citrus fruits and peels on human oral epidermoid carcinoma cells, the experiments show that the hesperetin, naringenin and nobiletin have an obvious effect on inhibiting proliferation of human oral epidermoid carcinoma cells, and the effect of the nobiletin on inhibiting oral cancer cells is most obvious, so that the nobiletin can be used for preparing health products and medicines with effects on preventing and treating oral cancer and is suitable for large-scale popularization and application.

The invention discloses a 22-nor-stigmasta thiosemicarbazone compound and a preparing method and application thereof. The structural formula of the 22-nor-stigmasta thiosemicarbazone compound is shown in the description. In vitro cancer cell growth and proliferation activity inhibition tests show that the prepared 22-nor-stigmasta thiosemicarbazone compound has a remarkable inhibition effect on various tumor cell strains such as human nipple thyroid gland cancer cells, human oral cavity epidermoid carcinoma cells and cervical cancer. Meanwhile, the 22-nor-stigmasta thiosemicarbazone compound is free of cytotoxicity on human kidney epithelial cells (HEK293T) and can be used for preparing medicine for treating cancer.

The invention belongs to the field of medicines and particularly relates to an application of physcion and a derivative thereof in preparation of antitumor drugs. The activity of a liver cancer cell, a lung cancer cell, a breast cancer cell, a colon cancer cell, a nasopharynx cancer cell, a gastric cancer cell, a human oral epidermoid carcinoma cell and a chronic myelogenous leukemia cell can be effectively inhibited by employing a pharmaceutical composition containing the physcion and the derivative thereof as active components, and especially the pharmaceutical composition has a more significant inhibition effect on the liver cancer cell, the lung cancer cell and the colon cancer cell. The physcion and the derivative thereof have an anti-tumor effect of inhibiting transplantation tumor growth for tumor-bearing nude mice with a liver cancer, a lung cancer and a colon cancer. Furthermore, the physcion and the derivative thereof have no toxic and side effect on a normal body. A foundation is laid for development of high-efficiency and low-toxicity novel broad-spectrum anti-tumor drugs of the physcion and the derivative thereof.

The invention relates to an application of a compound marsdenia tenacissima glycoside B which is extracted and separated from natural plant marsdenia tenacissima in the preparation of a drug for remedying tumour diseases including various malignant tumour diseases, such as ovary cancer, stomach cancer, liver cancer, leucocythemia, lung cancer, oral epidermoid carcinoma, rectal adenocarcinoma, breast cancer, malignant melanocarcinoma, colon adenocarcinoma, nasopharyngeal carcinoma, prostate cancer, etc. The invention also relates to a preparation technology of the marsdenia tenacissima glycoside B. After using water extraction and alcohol sedimentation, the invention uses an innovative chloroform extraction and aether sedimentation technology by chloroform extraction and also creatively adding aether, thereby reducing the content of impurity in extract obviously, and the marsdenia tenacissima glycoside B with high purity can be obtained just by silica gel column separation at a time. The method has high yield and simple operation, does not require a preparation type precision instrument of high performance liquid phase and other similar instruments and is closer to the requirement of the industrialized production.

The invention relates to macrocyclic diterpenoid compounds separated from euphorbia macrorrhiza C.A.Mey and application. The macrocyclic diterpenoid compounds separated from euphorbia macrorrhiza C.A.Mey respectively belong to five different diterpenoid scaffold types. The macrocyclic diterpenoid compounds are subjected to in-vitro cytotoxic activity determination and anti-drug-resistance activity determination. Experiment results show that the macrocyclic diterpenoid compounds separated from euphorbia macrorrhiza C.A.Mey have cytotoxic activity on human oral-cavity epidermoid carcinoma KB cell and human oral-cavity epidermoid carcinoma drug-resistant strain KBv200 to different degrees, have certain anti-drug-resistance activity, and is applicable to antitumor medicines.

The present invention provides methods and compositions for the diagnosis and treatment of cancer, including cancers involving the NOTCH pathway. In particular, the present invention provides methods and compositions for the diagnosis of mucoepidermoid carcinoma, the most common malignant salivary gland tumor. The present invention further provides methods and compositions for the diagnosis of other tumors associated with the t(11;19)(q14–21;12–13) translocation.

The invention discloses a siRNA sequence for inhibiting survivin gene expression. The siRNA sequence has the broad spectrum siRNA anti-tumor effect, and the excellent inhibiting effect on breast cancer, lung cancer, intestinal cancer, liver cancer, leukemia, stomach cancer, cervical cancer, human oral epidermoid carcinoma and the like in vitro, particularly on breast cancer, lung cancer and cervical cancer cells. When the siRNA double-strand sequence enters an organism through a certain manner, the expression of disease related protein can be efficiently and specifically inhibited, so that related disease genes are silent, the target gene expression can be effectively knocked out, and the treating purpose can be achieved.

The invention discloses a 7 site-connected bis(beta-carboline alkaloid) compound and its preparation method, pharmaceutical composition and use. The bis(beta-carboline alkaloid) compound and its medicinal salt are shown in the general formula I. The bis(beta-carboline alkaloid) compound is prepared by condensation of a beta-carboline intermediate and dihalogenated alkane. The invention discloses a pharmaceutical composition. The pharmaceutical composition comprises an effective dose of the bis(beta-carboline alkaloid) compound shown in the formula I and pharmaceutically acceptable carriers. The invention relates to a use of the bis(beta-carboline alkaloid) compound in preparation of drugs for resisting cancers such as melanoma, stomach cancer, lung cancer, breast cancer, kidney cancer, liver cancer, human oral epidermoid carcinoma, cervical carcinoma, ovarian cancer, pancreas cancer, prostate cancer and colorectal carcinoma.

The invention relates to treatment of cancer. More specifically the invention relates to methods of treating cancer selected from the group consisting of squamous cell cancer, lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer, as well as B-cell lymphoma including low grade/follicular non-Hodgkin's lymphoma (NHL); small lymphocytic (SL) NHL; intermediate grade/follicular NHL; intermediate grade diffuse NHL; high grade immunoblastic NHL; high grade lymphoblastic NHL; high grade small non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma; AIDS-related lymphoma; and Waldenstrom's Macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairy cell leukemia; chronic myeloblastic leukemia; and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal vascular proliferation associated with phakomatoses, edema such as that associated with brain tumors, Meigs' syndrome, melanoma, mesothelioma, multiple myeloma, fibrosarcoma, osteosarcoma and epidermoid carcinoma, by administering antibodies directed to α2β1 integrin.

The invention provides 2,4-diarylamine pyrimidine derivatives containing hydroxamic acid fragments shown in formulas I and II. 2,4-diarylamine pyrimidine containing carboxyl fragments is mainly used as a parent nucleus and is subjected to single-step condensation and related modification with hydroxylamine protected by THP to obtain a target compound. An experiment proves that the remarkable anti-proliferative effect is achieved for tumor cells (a human lung adenocarcinoma cell line H1975 and an overexpression EGFR human epidermal carcinoma cell line A431) related to EGFR tyrosine kinase activity on the cellular level, and a human cervical carcinoma cell line Hela, a human oral epidermoid carcinoma cell line KB, a human promyelocytic acute leukemia cell line HL60, a human hepatoma cell line HepG2, a human colon cancer cell line SW620 and other tumor cells related to the HDAC histone acetylase activity, and the corresponding medicine for resisting cancer cells can be prepared. The general structural formula is shown in the description.